Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity.
Sulfur mustard (SM) is highly toxic to the lung inducing both acute and chronic effects including upper and lower obstructive disease, airway inflammation, and acute respiratory distress syndrome, and with time, tracheobronchial stenosis, bronchitis, and bronchiolitis obliterans. Thus it is essential to identify effective strategies to mitigate the toxicity of SM and related vesicants. Studies in animals and in cell culture models have identified key mechanistic pathways mediating their toxicity, which may be relevant targets for the development of countermeasures. For example, following SM poisoning, DNA damage, apoptosis, and autophagy are observed in the lung, along with increased expression of activated caspases and DNA repair enzymes, biochemical markers of these activities. This is associated with inflammatory cell accumulation in the respiratory tract and increased expression of tumor necrosis factor-α and other proinflammatory cytokines, as well as reactive oxygen and nitrogen species. Matrix metalloproteinases are also upregulated in the lung after SM exposure, which are thought to contribute to the detachment of epithelial cells from basement membranes and disruption of the pulmonary epithelial barrier. Findings that production of inflammatory mediators correlates directly with altered lung function suggests that they play a key role in toxicity. In this regard, specific therapeutic interventions currently under investigation include anti-inflammatory agents (e.g., steroids), antioxidants (e.g., tocopherols, melatonin, N-acetylcysteine, nitric oxide synthase inhibitors), protease inhibitors (e.g., doxycycline, aprotinin, ilomastat), surfactant replacement, and bronchodilators. Effective treatments may depend on the extent of lung injury and require a multi-faceted pharmacological approach.
Weinberger
Barry
B
Department of Pediatrics, Division of Neonatology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place, New Brunswick, NJ 08903, USA. weinbebi@umdnj.edu
Laskin
Jeffrey D
JD
Sunil
Vasanthi R
VR
Sinko
Patrick J
PJ
Heck
Diane E
DE
Laskin
Debra L
DL
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000187:drug effects*; D023421:Models, Animal; D009151:Mustard Gas / Q000633:toxicity*; D011480:Protease Inhibitors / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D011480:Protease Inhibitors; D011663:Pulmonary Surfactants; D009151:Mustard Gas